Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
The prospective registration of completely resected high-risk stage III melanoma patients treated with dabrafenib and trametinib in the adjuvant setting was based on collaboration with centers of excellence on melanoma patients treatment. Pre-identified centers considered as the most advanced according to their knowledge and experience, took part in the patients recruitment.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with complete surgical resection of histologically confirmed AJCC (8th edition) clinical stage III (stage IIIA \[lymph node \> 1mm\],, IIIB, IIIC, IIID) melanoma, in whom a decision for adjuvant treatment with dabrafenib and trametinib has been made before entering the study;
V600E mutation-positive cutaneous melanoma;
≥ 18 years of age;
Written informed consent signed.
You may not be if
Lack of basic demographic and staging data.
Current active participation in an interventional clinical trial for treatment of melanoma.
Pregnancy or breastfeeding women.
Current primary diagnosis of a cancer other than melanoma, that requires systemic or other treatment.
Clareo Health | Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.
